Genome & Co.’s bile duct cancer drug candidate enters Phase 2 trials

Genome & Co.’s bile duct cancer drug candidate enters Phase 2 trials

Genome & Company, a South Korean developer of microbiome-based drugs, on Tuesday said its GEN-001, a leading immunotherapy drug candidate for bi...

S.Korea's NGeneBio establishes US corporation NGeneBioAI

S.Korea's NGeneBio establishes US corporation NGeneBioAI

South Korean medical diagnostic company NGeneBio Co. announced on Monday that it has established an artificial intelligence (AI) precision diagnosti...

Korea’s Genome & Company aims US CMO market

Korea’s Genome & Company aims US CMO market

South Korea’s microbiome medicine developer Genome & Company geared up for entering the U.S. market to boost profits and make inroads into...

Kakao Pay backs out of acquisition deal for SSG Pay, Smile Pay Hanwha in talks to buy five-star hotel Paraspara Seoul Kia's Lego-like PV5 with 16 variants to hit market in July Stray Kids make K-pop history with landmark stadium show in Germany S.Korea’s most prominent business leader returns with all charges cleared
banner